Melissa Kelley joined the Penn Memory Center in 2019 as a Clinical Research Coordinator for the ABC study focusing on the MRI sub-study. She currently serves as the coordinator for the TRAILBLAZER-ALZ2 trial investigating the efficacy of donanemab for early-stage AD patients. She also helps administer cognitive testing to participants and clinic patients. Prior to her work at PMC, she served as an undergraduate research assistant, working on studies involving transcranial magnetic stimulation (TMS) as an intervention for patients recovering from stroke. She earned her bachelor’s degree in exercise science and a minor in psychology from the University of Delaware in 2016.